20.500.12556/DiRROS-19163 Premalignant gastric lesions in patients included in National colorectal cancer screening Background. Gastric cancer is the fifth most common malignancy in the world with almost one million new cases annually. Helicobacter pylori infection causes 89% of all gastric cancers. Premalignant lesions (atrophy and intestinal metaplasia) develop after several decades of inflammation. Secondary prevention with gastroscopy is possible, but it is costly and has a low compliance rate. Alternative procedures like serology testing for pepsinogen I and II and pepsinogen I/II ratio are available to select patients for surveillance gastroscopies. Patients and methods. In seven outpatient endoscopic units, 288 patients (154 men; 53.5%), average age 60.68 years, tested positive in National colorectal cancer screening programme SVIT, were included in the study. Gastropanel (BioHit, Finland) was used as a serologic biopsy method. Results. We found 24 patients (12 men, mean age 63.7 years) with pepsinogen (pepsinogen I/II < 3 and/or pepsinogen I < 30 %g/L). Premalignant changes were found on gastric biopsies in 21 patients (7.3% incidence). Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) % 1 was found in 20 patients; Operative Link for Gastritis Assessment (OLGA) % 1 was found in 19 patients. Combined accuracy for preneoplastic lesions in Gastropanel positive patients was 87.5%. H. pylori seropositivity was found in 219 patients (76%). Only 24% of our population had normal results. Conclusions. Gastropanel test has proven to be a reliable non-invasive test for advanced gastric preneoplastic lesions that can select patients for further gastroscopy. We found high H. pylori seropositivity in older age groups in Slovenia. Helicobacter pylori gastropanel atrophy Slovenia intestinal metaplasia gastric cancer SVIT true false true Association of Radiology and Oncology Ljubljana Angleški jezik Slovenski jezik by Authors Neznano 2024-07-02 13:13:37 2024-07-02 13:13:37 2024-07-03 03:39:48 0000-00-00 00:00:00 2018 0 0 Soavtorji: Maja Seruga, Miroslav Vujasinovic, Dejan Urlep, Liljana Ljepovic, Jurecic Nataša Brglez, Alenka Forte, Ljubec Anita Kek, Miha Skvarc; str. 7-13, I no. 1 Vol. 52 2018 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2018-01-01 616.3 1318-2099 10.1515/raon-2017-0054 93861121 RAZ_Tepes_Bojan_2018.pdf RAZ_Tepes_Bojan_2018.pdf 1 295742E08CE538BC68B44DA473995A0C 4f268ab2a2a7882e5f97bd7d2a7c3a734606b04fa73fb7208129f3751b23917c 4bd0c4c6-3864-11ef-b487-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=26381 Onkološki inštitut Ljubljana 0 0 0